WHO & Regional Offices [to 12 Sep 2020]
10 September 2020
Statement
Statement from the first ACT-Accelerator Facilitation Council meeting
[See Milestones above for detail]

News release
Coronavirus Global Response: Access to COVID-19 Tools-Accelerator Facilitation Council holds inaugural meeting
:: United Nations Secretary General António Guterres appeals for a quantum leap in funding for the ACT-Accelerator, a global solution to get the world moving, working and prospering again
:: H.E. Cyril Ramaphosa, President of South Africa, and H.E. Erna Solberg, Prime Minister of Norway, co-chair the ACT-Acceleration Facilitation Council
:: Global leaders – including over 30 heads of state and ministers – release statement of commitment to galvanizing support for the ACT-Accelerator and the need for the financial resources required to leave no one behind
:: ACT-Accelerator calculates that $35 billion is still required to give all countries the tools needed to end the pandemic as quickly as possible

9 September 2020 News release
COVID-19 could reverse decades of progress toward eliminating preventable child deaths, agencies warn

9 September 2020 News release
More than 3 billion people protected from harmful trans fat in their food

8 September 2020 News release
WHO calls for global action on sepsis – cause of 1 in 5 deaths worldwide

::::::

Weekly Epidemiological Record, 11 September 2020, vol. 95, 37 (pp. 441–448)
Cholera 2019

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: COVID-19 genome sequencing laboratory network launches in Africa 10 September 2020
:: Noncommunicable diseases increase risk of dying from COVID-19 in Africa 10 September 2020

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
No new digest content identified

WHO European Region EURO
:: Digital health: transforming and extending the delivery of health services 09-09-2020
:: WHO Regional Director for Europe gives update on the work of the Regional Office ahead of virtual Regional Committee 09-09-2020
:: Health priorities for the European Region and COVID-19 in focus at WHO annual meeting 08-09-2020
:: A new international day to celebrate clean air – and a sustainable recovery from COVID-19 07-09-2020

WHO Eastern Mediterranean Region EMRO
:: WHO provides medical supplies to Sudan following major flooding 9 September 2020
:: UNICEF, WHO support Sudan’s efforts to end vaccine-derived polio outbreak 8 September 2020

WHO Western Pacific Region
No new digest content identified

Announcements

Paul G. Allen Frontiers Group [to 12 Sep 2020]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

BARDA – U.S. Department of HHS [to 12 Sep 2020]
https://www.phe.gov/about/barda/Pages/default.aspx
BARDA News
No new digest content identified.

BMGF – Gates Foundation [to 12 Sep 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 12 Sep 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 12 Sep 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 12 Sep 2020]
http://cepi.net/
Latest News
No new digest content identified.

EDCTP [to 12 Sep 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

Emory Vaccine Center [to 12 Sep 2020]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Medicines Agency [to 12 Sep 2020]
http://www.ema.europa.eu/ema/
News & Press Releases
No new digest content identified.

European Vaccine Initiative [to 12 Sep 2020]
http://www.euvaccine.eu/
Latest News
No new digest content identified.

FDA [to 12 Sep 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
September 11, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 11, 2020
… In a new FDA Voices entitled, The FDA’s Scientific and Regulatory Oversight of Vaccines is Vital to Public Health, agency leaders explain that they are committed to making decisions that are guided by science and data regarding the authorization or approval of COVID-19 vaccines.
… FDA issued a temporary guidance, “Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency,” to help drug and biological product manufacturers (including animal drug manufacturers) transition from operations impacted by the COVID-19 public health emergency to normal manufacturing operations.

September 10, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 10, 2020

September 9, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 9, 2020

September 8, 2020 – Coronavirus (COVID-19) Update: Daily Roundup September 8, 2020
…The FDA has deactivated the FDA registration for 340 foreign establishments that failed to identify a U.S. Agent as required by FDA’s regulations.  Of these, 131 establishments list devices that are essential to the COVID-19 pandemic response.
…Testing updates: To date, the FDA has currently authorized 243 tests under EUAs; these include 195 molecular tests, 44 antibody tests, and 4 antigen tests.

Fondation Merieux [to 12 Sep 2020]
http://www.fondation-merieux.org/
News, Events
Mérieux Foundation co-organized event
ACDx Webinar focused on the critical role of diagnostics in the COVID-19 pandemic – 4 regional perspectives
September 15, 2020 – Webinar 3:00pm to 5:00pm (CET)
The COVID-19 pandemic has highlighted the major role of diagnostics in the patient’s management. Around the globe, the regions and countries have put in place different diagnostics strategies and policies to tackle this COVID-19 sanitary crisis.
The Mérieux Foundation and the London School of Hygiene & Tropical Medicine (LSHTM) are jointly organizing a 2 hour webinar on September 15 at 3pm (CET) on the critical role of diagnostics in the COVID-19 crisis management to share best practices & lessons learnt from experiences around the world.

Gavi [to 12 Sep 2020]
https://www.gavi.org/
News releases
No new digest content identified.

GHIT Fund [to 12 Sep 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund [to 12 Sep 2020]
https://www.theglobalfund.org/en/news/
News/Updates
COVID-19 Response: Corticosteroids
08 September 2020
Following the World Health Organization guidance Corticosteroids for COVID-19 from 2 September, the Global Fund has confirmed that corticosteroids can be funded through Global Fund grants.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 12 Sep 2020]
https://www.glopid-r.org/news/
News
Mérieux Foundation seeks Scientific and Advocacy Director for the GloPID-R Secretariat
01/09/2020
Since 2015, the GloPID-R alliance has been pursuing its objectives to increase preparedness and facilitate rapid research response to outbreaks…

Hilleman Laboratories [to 12 Sep 2020]
http://www.hillemanlabs.org/
No new digest content identified.

Human Vaccines Project [to 12 Sep 2020]
http://www.humanvaccinesproject.org/media/press-releases/
Press Release
No new digest content identified.

IAVI [to 12 Sep 2020]
https://www.iavi.org/newsroom
FEATURES
September 8, 2020
IAVI Researchers Publish Study on Antibody Responses to HIV Immunogen in Non-human Primates
Researchers at IAVI’s Neutralizing Antibody Center (NAC), Scripps Research, and other partner organizations have identified and isolated a suite of neutralizing HIV antibodies that develop in rhesus macaques in response to immunization with BG505 SOSIP. This immunogen is the basis of several HIV vaccine candidates now in Phase I clinical trials, including the IAVI W001 trial. Their findings were published in Cell Reports on September 8, 2020…

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

IFFIm
http://www.iffim.org/
Announcements
No new digest content identified.

IFRC [to 12 Sep 2020]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Europe, Greece
Residents of Moria camp must be moved now – Red Cross head
Around 13,000 people are lacking food, water and shelter, after devastating fires on Tuesday and Wednesday this week. At the time of the first fire the camp was under lockdown due to more than 30 COVID19 positive cases.
11 September 2020

Africa, Sudan
Red Cross launches Emergency Appeal for Sudan as deadly flooding leaves thousands homeless
Nairobi/Geneva, 11 September 2020 — The International Federation of Red Cross and Red Crescent Societies (IFRC) today launched an additional funds appeal for 12 million Swiss Francs to support the Sudanese Red Crescent Society (SRCS) in delivering assi …
11 September 2020

Global
Red Cross Red Crescent turns to Rakuten Viber to fight COVID-19 infodemic
Geneva, 10 September 2020 – The International Federation of Red Cross and Red Crescent Societies (IFRC) and the Croatian Red Cross today signed a new partnership agreement with global messaging app Rakuten Viber to engage new online audiences with trus …
10 September 2020

Global
Migrants and refugees “least protected, most affected” in COVID crisis, warns IFRC President
Geneva, 10 September 2020 – The COVID-19 pandemic has been a disaster for people from all walks of life, but an absolute “catastrophe” for the world’s vulnerable migrants, people seeking asylum and refugees. Already weak social safety nets are eroding, …
10 September 2020

Global
IFRC’s first ever virtual climate summit, Climate:Red, is happening everywhere on 9-10 September 
Geneva, 8 September 2020 – Climate:Red, a fully virtual and truly global climate change summit, is bringing youth champions, activists, indigenous leaders, scientists and government ministers together on 9 – 10 September 2020 for 30 hours of innovation …
8 September 2020

IRC International Rescue Committee [to 12 Sep 2020]
http://www.rescue.org/press-release-index
Media highlights {Selected]
Press Release
As the threat of resettlement postponement looms, IRC urges the Trump Administration to set refugee admissions cap to at least 95,000 by September 30
September 11, 2020

Press Release
International Rescue Committee’s Pakistan Reading Project Wins 2020 International Prize from the Library of Congress
September 10, 2020

Statement
New UN report details ongoing atrocities in Yemen; IRC calls for immediate ceasefire
September 10, 2020

Press Release
New Research Finds Lack of Access to Adequate Child Care As One of the Top Barriers to Economic Empowerment for Refugee Women
September 10, 2020

Press Release
Over 12,000 people left stranded in Lesvos after a fire engulfs Moria reception centre; IRC providing mental health support to survivors
September 9, 2020

IVAC [to 12 Sep 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
Webinar: Avoiding Barriers to Access for a COVID-19 Vaccine
Register: The International Vaccine Access Center (IVAC) on September 16, 2020 at 8:00 EDT/21:00 KST will host a 60-minute webinar, “Avoiding Barriers to Access for a COVID-19 Vaccine.”
Description: Even before the COVID-19 pandemic, countries worked to overcome a myriad of challenges when introducing new safe and effective vaccines. While policy makers and health advocates addressed barriers, from understanding disease burden and cost effectiveness to establishing cold chain systems, preventable diseases spread, sicken populations, and cost lives. Learning from the past failures of vaccine introductions will be crucial for ensuring equitable access to a COVID-19 vaccine. Leaders and scientists in the international vaccine field will discuss the barriers to vaccine access we must overcome to avoid and the role the international community will play in promoting equity in delivering a COVID-19 vaccine.

IVI [to 12 Sep 2020]
http://www.ivi.int/
Selected IVI News & Announcements
IVI to ready clinical trial sites for COVID-19 vaccine efficacy trials in 4 countries
September 9, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI) announced today that the Bill & Melinda Gates Foundation awarded close to 1.5 million USD to IVI to support clinical trial site preparedness in four African and Asian countries to potentially support future COVID-19 Phase III efficacy vaccine trials.
[See COVID-19 above for detail]

JEE Alliance [to 12 Sep 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières [to 12 Sep 2020]
http://www.msf.org/
Latest [Selected Announcements]
Myanmar
MSF hands over long-running HIV project in Yangon to ministry of …
Project Update 10 Sep 2020

Greece
All people in Moria camp must be evacuated to safety in wake of destru…
Project Update 9 Sep 2020

Pakistan
Meeting regular health needs amid the COVID-19 pandemic in…
Project Update 8 Sep 2020

Nigeria
“Children can draw assault rifles better than a football” in Borno state
Interview 8 Sep 2020

National Vaccine Program Office – U.S. HHS [to 12 Sep 2020]
https://www.hhs.gov/vaccines/about/index.html
NVAC Meetings
September 23-24, 2020 Meeting (Virtual)
Selected Agenda Topics:
:: Serving Up Equity: Health-In-All Approaches for COVID-19 Vaccination [Panel]
:: Allocation and Prioritization: Considerations and Recommendations for the Distribution of
COVID-19 Vaccines [Dr. Ezekiel Emanuel, University of Pennsylvania; CDC tbd]
:: Perspectives from the Field: Operation Warp Speed [Dr. Moncef Slaoui, HHS]
:: The Infodemic, COVID-19 Immunization, and the Public’s Health [Panel]
:: Immunization Information Systems to Support the COVID-19 Response [Panel]

NIH [to 12 Sep 2020]
http://www.nih.gov/news-events/news-releases
Selected News Releases
NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19
September 10, 2020
The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.
Collectively known as ACTIV-4 Antithrombotics, the trials will provide critical insights that could help guide the care of patients with COVID-19, particularly those who suffer from life-threatening blood clots. The trial for hospitalized COVID-19 patients and the trial for patients with COVID-19 who have not been hospitalized are now underway. A third trial to start later will focus on patients discharged after hospitalization for moderate to severe COVID-19 disease. All three clinical trials will be coordinated and overseen by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, and funded through Operation Warp Speed(link is external)…

PATH [to 12 Sep 2020]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Sabin Vaccine Institute [to 12 Sep 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 12 Sep 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
9 September 2020
Cash donations for people who use drugs during COVID-19 in Bangladesh

UNICEF [to 12 Sep 2020]
https://www.unicef.org/media/press-releases
Selected Press releases/Announcements
Statement
09/11/2020
UNICEF statement on children affected by the Moria camp fire on Lesvos Island, Greece

Statement
09/11/2020
Polio programme accelerates efforts to respond to new polio outbreaks in Sudan and Yemen
Joint statement by WHO Regional Director for the Eastern Mediterranean Region Dr Ahmed Al Mandhari and UNICEF Regional Director for the Middle East and North Africa Region Ted Chaiban

Statement
09/10/2020
UNICEF Executive Director Henrietta Fore’s remarks at the UN Security Council Open Debate on Children and Armed Conflict: Attacks against schools as a grave violation of children’s rights
This is a summary of what was said by Henrietta Fore, UNICEF Executive Director – to whom quoted text may be attributed – at today’s Security Council Open Debate at the United Nations in New York. Checked against delivery.

Press release
09/10/2020
The Time to Prepare for COVID-19 Vaccine Transport is Now
[See COVID-19 above for detail]

Statement
09/10/2020
Remarks by UNICEF Executive Director Henrietta Fore at the 2020 Executive Board Session

Press release
09/09/2020
More than half a million children under five in Burkina Faso are acutely malnourished – UNICEF

Statement
09/09/2020
UNICEF statement on fire at Moria Camp in Lesvos, Greece

Press release
09/08/2020
COVID-19 could reverse decades of progress toward eliminating preventable child deaths, agencies warn
With the number of under-five deaths at an all-time recorded low of 5.2 million in 2019, disruptions in child and maternal health services due to the COVID-19 pandemic are putting millions of additional lives at stake

Unitaid [to 12 Sep 2020]
https://unitaid.org/
Featured News
No new digest content identified.

Vaccination Acceptance Research Network (VARN) [to 12 Sep 2020]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.

Vaccine Confidence Project [to 12 Sep 2020]
http://www.vaccineconfidence.org/
Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 12 Sep 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

Wellcome Trust [to 12 Sep 2020]
https://wellcome.ac.uk/news
Explainer | 11 September 2020
Safety first: how to run a Covid-19 vaccine clinical trial
The world is waiting eagerly for Covid-19 vaccines to be developed as quickly as possible. But to make sure they are safe and effective, the clinical trials that test them have to be robust. So how do trials achieve this?

Opinion | 7 September 2020
The first Covid-19 vaccine may not be the magic bullet that returns life to ‘normal’
Jeremy Farrar
Director Wellcome
As we’ll soon start to see the results of the first vaccines coming through late-stage clinical trials, Jeremy Farrar explains why we should be cautiously optimistic.

The Wistar Institute [to 12 Sep 2020]
https://www.wistar.org/news/press-releases
Press Releases
Sep. 10, 2020
Scientists Engineer DNA-based Nanotechnology to Stimulate Potent Antitumor Immune Responses in Preclinical Models
Synthetic DNA nanovaccines enhance killer T cell immunity resulting in tumor control in preclinical studies.

Press Release
Sep. 7, 2020
The BEAT-HIV Martin Delaney Collaboratory Issues Recommendations on Measuring Persistent HIV Reservoirs in Cure-directed Clinical Trials
The consortium provides first authoritative viewpoint on which viral measurements to prioritize when evaluating the impact of potential therapeutic strategies to eradicate HIV.

WFPHA: World Federation of Public Health Associations [to 12 Sep 2020]
https://www.wfpha.org/
Latest News
No new digest content identified.

World Organisation for Animal Health (OIE) [to 12 Sep 2020]
https://www.oie.int/en/for-the-media/press-releases/2020/
Press Releases
No new digest content identified.

::::::

ARM [Alliance for Regenerative Medicine] [to 12 Sep 2020]
https://alliancerm.org/press-releases/
Press Releases
No new digest content identified.

BIO [to 12 Sep 2020]
https://www.bio.org/press-releases
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 12 Sep 2020]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 12 Sep 2020]
https://internationalbiotech.org/
News
No new digest content identified.

IFPMA [to 12 Sep 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
COVID-19 Vaccine Maker Pledge
08 September 2020
[See COVID-19 Vaccines above for detail]

PhRMA [to 12 Sep 2020]
http://www.phrma.org/
Selected Press Releases, Statements
PhRMA member companies invested $83 billion in research and development last year
Tim McClung   |     September 10, 2020   |
PhRMA member companies invested $83 billion in research and development (R&D) in 2019, the highest level of investment on record, according to the 2020 PhRMA member annual survey. Over the past two decades, PhRMA member companies have invested a grand total of nearly $1 trillion in the search for and development of new and better treatments and cures.
America’s biopharmaceutical companies are at the heart of a robust R&D ecosystem that develops more innovative medicines than any other country in the world. There are nearly 260 vaccines in development for the treatment or prevention of disease, including numerous different types of potential vaccines that target COVID-19…

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 12 Sep 2020)

Debate Open Access
Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy
Authors: Sebastian Schleidgen, Hans-Georg Dederer, Susan Sgodda, Stefan Cravcisin, Luca Lüneburg, Tobias Cantz and Thomas Heinemann
11 September 2020
Abstract
Background
Clustered Regularly Interspaced Short Palindromic Repeats-associated (CRISPR-Cas) technology may allow for efficient and highly targeted gene editing in single-cell embryos. This possibility brings human germline editing into the focus of ethical and legal debates again.
Main body
Against this background, we explore essential ethical and legal questions of interventions into the human germline by means of CRISPR-Cas: How should issues of risk and uncertainty be handled? What responsibilities arise regarding future generations? Under which conditions can germline editing measures be therapeutically legitimized? For this purpose, we refer to a scenario anticipating potential further development in CRISPR-Cas technology implying improved accuracy and exclusion of germline transmission to future generations. We show that, if certain concepts regarding germline editing are clarified, under such conditions a categorical prohibition of one-generation germline editing of single-cell embryos appears not to be ethically or legally justifiable.
Conclusion
These findings are important prerequisites for the international debate on the ethical and legal justification of germline interventions in the human embryo as well as for the harmonization of international legal standards.

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 12 Sep 2020)

Preparing for a pandemic: highlighting themes for research funding and practice—perspectives from the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)
The Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) is an international network of global health funders and stakeholders formed in 2013 to ensure preparedness for a coordinated research response to epidemics and pandemics [1]. GloPID-R aims to address challenges to effective research in epidemics and pandemics, through both preparedness and response activities.
Authors: Alice Norton, Louise Sigfrid, Adeniyi Aderoba, Naima Nasir, Peter G. Bannister, Shelui Collinson, James Lee, Geneviève Boily-Larouche, Josephine P. Golding, Evelyn Depoortere, Gail Carson, Barbara Kerstiëns and Yazdan Yazdanpanah
Citation: BMC Medicine 2020 18:273
Content type: Commentary
Published on: 8 September 2020

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 12 Sep 2020)

Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017
In December 2016, three cases of serogroup B invasive meningococcal disease, including two children from the same middle school (11 to 15 years old pupils), occurred in the department (administrative district)…
Authors: Mathilde Pivette, Muhamed-Kheir Taha, Anne-Sophie Barret, Elisabeth Polard, Marie-Bernadette Hautier, Jean-Benoît Dufour, Marlène Faisant, Lisa Antoinette King, Denise Antona, Daniel Levy-Bruhl, Hélène Tillaut, Alexandre Scanff, Camille Morival, José-Hector Aranda Grau, Pierre Guillaumot and Bertrand Gagnière
Citation: BMC Public Health 2020 20:1382
Content type: Research article
Published on: 10 September 2020

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 12 Sep 2020)

Impact of an influenza information pamphlet on vaccination uptake among Polish pupils in Edinburgh, Scotland and the role of social media in parental decision making
In Edinburgh, Scotland, lower influenza vaccine uptake has been observed in primary school children in the Polish community.
Authors: K. Bielecki, J. Craig, L. J. Willocks, K. G. Pollock and D. R. Gorman
Citation: BMC Public Health 2020 20:1381
Content type: Research article
Published on: 10 September 2020

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 12 Sep 2020)

Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model
Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularl…
Authors: Pascal Crépey, Louis Boiron, Rafael Rodrigo Araujo, Juan Guillermo Lopez, Audrey Petitjean and Expedito José de Albuquerque Luna
Citation: BMC Public Health 2020 20:1374
Content type: Research article
Published on: 9 September 2020

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 12 Sep 2020]

Addressing COVID-19 in humanitarian settings: a call to action
Authors: Jude Alawa, Nawara Alawa, Adam Coutts, Richard Sullivan, Kaveh Khoshnood and Fouad M. Fouad
Citation: Conflict and Health 2020 14:64
Content type: Commentary
Published on: 10 September 2020
Abstract
Refugees and internally displaced persons in humanitarian settings are particularly susceptible to the spread of infectious illnesses such as COVID-19 due to overcrowding and inadequate access to clean water, sanitation, and hygiene facilities. Countries facing conflict or humanitarian emergencies often have damaged or fragmented health systems and little to no capacity to test, isolate, and treat COVID-19 cases. Without a plan to address COVID-19 in humanitarian settings, host governments, aid agencies, and international organizations risk prolonging the spread of the virus across borders, threatening global health security, and devastating vulnerable populations. Stakeholders must coordinate a multifaceted response to address COVID-19 in humanitarian settings that incorporates appropriate communication of risks, sets forth resource-stratified guidelines for the use of limited testing, provides resources to treat affected patients, and engages displaced populations.

Globalization and Health
http://www.globalizationandhealth.com/

Articles
Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study
The recent innovation activities of global top-tier pharmaceutical companies in accordance with global and regional health concerns were investigated in order to identify their innovations contributing to popu…
Authors: Ye Lim Jung, JeeNa Hwang and Hyoung Sun Yoo
Citation: Globalization and Health 2020 16:80
Content type: Research
Published on: 10 September 2020

Health Affairs
Vol. 39, No. 9 September 2020
https://www.healthaffairs.org/toc/hlthaff/current

Research Article COVID-19
Designing Pull Funding For A COVID-19 Vaccine
Christopher M. Snyder, Kendall Hoyt, Dimitrios Gouglas, Thomas Johnston, and James Robinson

Health Affairs
Vol. 39, No. 9 September 2020
https://www.healthaffairs.org/toc/hlthaff/current

Medicare Payment Incentives, Medicaid & More
Research Article Global Health Policy
Restrictions On US Global Health Assistance Reduce Key Health Services In Supported Countries
Jennifer Sherwood, Matthea Roemer, Brian Honermann, Austin Jones, Greg Millett, and Michele R. Decker

Health Economics, Policy and Law 
Volume 15 – Issue 4 – October 2020
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue

Article
HPV vaccine status and sexual behavior among young sexually-active women in the US: evidence from the National Health and Nutrition Examination Survey, 2007–2014
Andrew J. Leidner, Harrell W. Chesson, Makram Talih

JAMA Network
COVID-19 Update September 12, 2020

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA
September 8, 2020, Vol 324, No. 10, Pages 919-1016
https://jamanetwork.com/journals/jama/currentissue

Preliminary Communication
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes – Interim Analysis of 2 Randomized Clinical Trials
Shengli Xia, BS; Kai Duan, PhD; Yuntao Zhang, PhD; et al.
free access has active quiz
JAMA. 2020;324(10):951-960. doi:10.1001/jama.2020.15543
This interim analysis of 2 randomized trials compares adverse reactions and neutralizing antibody responses to inactivated coronavirus disease 2019 (COVID-19) vs adjuvant-only control vaccination, and compares the outcomes at varying vaccine doses among healthy adults in China.
…Conclusions and Relevance  In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials.
Trial Registration  Chinese Clinical Trial Registry Identifier: ChiCTR2000031809

JAMA
September 8, 2020, Vol 324, No. 10, Pages 919-1016
https://jamanetwork.com/journals/jama/currentissue

Editorial
An Inactivated Virus Candidate Vaccine to Prevent COVID-19
Mark J. Mulligan, MD
… In summary, this preliminary report by Xia et al¹⁰ provides important interim safety, tolerability, and immune response results for a β-propiolactone–inactivated whole-virus vaccine against COVID-19. These interim data are of interest given the urgent global need for protective COVID-19 vaccines. With 7.8 billion individuals worldwide at risk for SARS-CoV-2 infection and COVID-19 morbidity and mortality, humanity needs as many safe and protective COVID-19 vaccines as possible.

JAMA
September 8, 2020, Vol 324, No. 10, Pages 919-1016
https://jamanetwork.com/journals/jama/currentissue

Viewpoint
Unwavering Regulatory Safeguards for COVID-19 Vaccines
Anand Shah, MD; Peter W. Marks, MD, PhD; Stephen M. Hahn, MD
free access has active quiz has multimedia has audio
JAMA. 2020;324(10):931-932. doi:10.1001/jama.2020.15725
This Viewpoint from the FDA reviews the minimum safety and efficacy standards COVID-19 vaccine candidates would need to meet to be considered for approval, and affirms its commitments to evaluating both in diverse populations and to postmarketing surveillance as means to ensure that approval will meet the highest safety and regulatory standards based on science and evidence, not politics.

JAMA
September 8, 2020, Vol 324, No. 10, Pages 919-1016
https://jamanetwork.com/journals/jama/currentissue

Improving Physician Communication About Treatment Decisions – Reconsideration of “Risks vs Benefits”
Daniel J. Morgan, MD; Laura D. Scherer, PhD; Deborah Korenstein, MD
has audio
JAMA. 2020;324(10):937-938. doi:10.1001/jama.2020.0354
This Viewpoint emphasizes the importance of precise language to help patients make evidence-informed decisions in shared decision-making, and argues that references to “chances of harms and benefits” will be more understandable to patients than discussions of “probabilities of risks and benefits.”
Conversations with Dr Bauchner: Changing Language to Improve Physician Communication About Treatment Decisions

JAMA Pediatrics
September 2020, Vol 174, No. 9, Pages 815-916
http://archpedi.jamanetwork.com/issue.aspx

Viewpoint
Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19)
Thomas J. Hwang, AB; Adrienne G. Randolph, MD, MSc; Florence T. Bourgeois, MD, MPH
free access
JAMA Pediatr. 2020;174(9):825-826. doi:10.1001/jamapediatrics.2020.1888
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

JAMA Pediatrics
September 2020, Vol 174, No. 9, Pages 815-916
http://archpedi.jamanetwork.com/issue.aspx

Original Investigation
Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States
Sarah Mbaeyi, MD, MPH; Tracy Pondo, MSPH; Amy Blain, MPH; et al.
JAMA Pediatr. 2020;174(9):843-851. doi:10.1001/jamapediatrics.2020.1990
This cohort study examines the association between quadrivalent meningococcal conjugate vaccination and the incidence of meningococcal disease in US adolescents.

JAMA Pediatrics
September 2020, Vol 174, No. 9, Pages 815-916
http://archpedi.jamanetwork.com/issue.aspx

Association Between Human Papillomavirus Vaccination School-Entry Requirements and Vaccination Initiation
Jamie S. Ko, MPH; Cameron S. Goldbeck, MS; Eleonore B. Baughan, BS; et al.
has active quiz
JAMA Pediatr. 2020;174(9):861-867. doi:10.1001/jamapediatrics.2020.1852
This cross-sectional study examines initiation of human papillomavirus vaccination in US jurisdictions with vs those without policies requiring vaccination for school entry.

Journal of Empirical Research on Human Research Ethics
Volume 15 Issue 4, October 2020
http://journals.sagepub.com/toc/jre/current

Ethical Issues in Informed Consent
Informing Informed Consent for HIV Research
Laura M. Campbell, Emily W. Paolillo, Robert Bryan, Jennifer Marquie-Beck, David J. Moore, Camille Nebeker, Raeanne C. MooreFirst Published June 19, 2020; pp. 235–243

Journal of Empirical Research on Human Research Ethics
Volume 15 Issue 4, October 2020
http://journals.sagepub.com/toc/jre/current

Empirical Studies on Research Integrity and Research Misconduct
A Scenario-Based Methodology for Analyzing the Ethical, Legal, and Social Issues in Genomic Data Sharing
Rebekah McWhirter, Lisa Eckstein, Don Chalmers, Christine Critchley, Jane Nielsen, Margaret Otlowski, Dianne Nicol
First Published May 19, 2020; pp. 355–364

Journal of Pediatrics
September 2020 Volume 224, p1-194
http://www.jpeds.com/current

The Editors’ Perspectives
COVID-19: A teachable moment for vaccines and trust
Sarah S. Long
Published in issue: September 2020

Journal of Pediatrics
September 2020 Volume 224, p1-194
http://www.jpeds.com/current

Original Articles
Evaluation of a Vaccine-Communication Tool for Physicians
Julia R. Glanternik, Julia C. McDonald, Arnold H. Yee, Amanda Howell BA, Katrina N. Saba, R. Grant Mellor, Bruce Fireman, Nicola P. Klein
p72–78.e1
Published online: June 6, 2020

Journal of Pediatrics
September 2020 Volume 224, p1-194
http://www.jpeds.com/current

Commentary
Caring for the Vaccine-Hesitant Family: Evidence-Based Alternatives to Dismissal
Joshua T.B. Williams, Sean T. O’Leary, Abraham M. Nussbaum
p137–140
Published online: May 21, 2020

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 12 Sep 2020]

Commentary
The Urgent Need for Transparent and Accountable Procurement of Medicine and Medical Supplies in Times of COVID-19 Pandemic
Authors: Jillian Clare Kohler and Tom Wright
11 September 2020
Abstract
The COVID-19 pandemic has unleashed unprecedented and complex public policy issues. One that has emerged as a challenge for many countries globally is how to ensure the efficient and effective procurement of quality medical supplies. Existing corruption pressures on procurement—everything from undue influence to the outright bribery of public officials—has been amplified by the pandemic, and thus demands commensurate policy responses. We argue that transparency and accountability in procurement are essential to preventing the corruption risks that threaten the health and well-being of populations.

The Lancet
Sep 12, 2020 Volume 396 Number 10253 p735-798, e25-e29
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Global collaboration for health: rhetoric versus reality
The Lancet
[See Milestones above for full text]

The Lancet
Sep 12, 2020 Volume 396 Number 10253 p735-798, e25-e29
https://www.thelancet.com/journals/lancet/issue/current

Comment
COVID-19 vaccine trials should seek worthwhile efficacy
Philip Krause, Thomas R Fleming, Ira Longini, Ana Maria Henao-Restrepo, Richard Peto
for the World Health Organization Solidarity Vaccines Trial Expert Group

The Lancet Child & Adolescent Health
Aug 2020 Volume 4 Number 8 p555-640, e26-e34
https://www.thelancet.com/journals/lanchi/issue/current

Review
Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy
Lisa J Frigati, et al

Lancet Digital Health
Sep 2020 Volume 2 Number 9 e441-e492
https://www.thelancet.com/journals/landig/issue/current

Comment
Approaching autonomy in medical artificial intelligence
Danielle S Bitterman, Hugo J W L Aerts, Raymond H Mak

Lancet Digital Health
Sep 2020 Volume 2 Number 9 e441-e492
https://www.thelancet.com/journals/landig/issue/current

Viewpoint
The myth of generalisability in clinical research and machine learning in health care
Joseph Futoma, Morgan Simons, Trishan Panch, Finale Doshi-Velez, Leo Anthony Celi

Lancet Global Health
Sep 2020 Volume 8 Number 9 e1101-e1241
http://www.thelancet.com/journals/langlo/issue/current

Editorial
Water and sanitation in a post-COVID world
The Lancet Global Health

Lancet Global Health
Sep 2020 Volume 8 Number 9 e1101-e1241
http://www.thelancet.com/journals/langlo/issue/current

Articles
Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study
Alexandra B Hogan, et al
Summary
Background
COVID-19 has the potential to cause substantial disruptions to health services, due to cases overburdening the health system or response measures limiting usual programmatic activities. We aimed to quantify the extent to which disruptions to services for HIV, tuberculosis, and malaria in low-income and middle-income countries with high burdens of these diseases could lead to additional loss of life over the next 5 years.
Methods
Assuming a basic reproduction number of 3·0, we constructed four scenarios for possible responses to the COVID-19 pandemic: no action, mitigation for 6 months, suppression for 2 months, or suppression for 1 year. We used established transmission models of HIV, tuberculosis, and malaria to estimate the additional impact on health that could be caused in selected settings, either due to COVID-19 interventions limiting activities, or due to the high demand on the health system due to the COVID-19 pandemic.
Findings
In high-burden settings, deaths due to HIV, tuberculosis, and malaria over 5 years could increase by up to 10%, 20%, and 36%, respectively, compared with if there was no COVID-19 pandemic. The greatest impact on HIV was estimated to be from interruption to antiretroviral therapy, which could occur during a period of high health system demand. For tuberculosis, the greatest impact would be from reductions in timely diagnosis and treatment of new cases, which could result from any prolonged period of COVID-19 suppression interventions. The greatest impact on malaria burden could be as a result of interruption of planned net campaigns. These disruptions could lead to a loss of life-years over 5 years that is of the same order of magnitude as the direct impact from COVID-19 in places with a high burden of malaria and large HIV and tuberculosis epidemics.
Interpretation
Maintaining the most critical prevention activities and health-care services for HIV, tuberculosis, and malaria could substantially reduce the overall impact of the COVID-19 pandemic.
Funding
Bill & Melinda Gates Foundation, Wellcome Trust, UK Department for International Development, and Medical Research Council.

Lancet Global Health
Sep 2020 Volume 8 Number 9 e1101-e1241
http://www.thelancet.com/journals/langlo/issue/current

Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17
Local Burden of Disease WaSH Collaborators

Lancet Global Health
Sep 2020 Volume 8 Number 9 e1101-e1241
http://www.thelancet.com/journals/langlo/issue/current

Real-world effectiveness of rotavirus vaccines, 2006–19: a literature review and meta-analysis
Eleanor Burnett, Umesh D Parashar, Jacqueline E Tate

Lancet Infectious Diseases
Sep 2020 Volume 20 Number 9 p993-1100, e215-e249
http://www.thelancet.com/journals/laninf/issue/current

Editorial
Air travel in the time of COVID-19
The Lancet Infectious Diseases

Lancet Infectious Diseases
Sep 2020 Volume 20 Number 9 p993-1100, e215-e249
http://www.thelancet.com/journals/laninf/issue/current

Comment
Vaccine development during global epidemics: the Zika experience
Priscila M S Castanha, Ernesto T A Marques

Lancet Infectious Diseases
Sep 2020 Volume 20 Number 9 p993-1100, e215-e249
http://www.thelancet.com/journals/laninf/issue/current

Sequential inactivated and oral poliovirus vaccine schedules: a balancing act
Khalequ Zaman, Abhijeet Anand

Lancet Infectious Diseases
Sep 2020 Volume 20 Number 9 p993-1100, e215-e249
http://www.thelancet.com/journals/laninf/issue/current

Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial
Hanqing He, et al

Lancet Public Health
Sep 2020 Volume 5 Number 9 e460-e511
https://www.thelancet.com/journals/lanpub/issue/current

Editorial
Will the COVID-19 pandemic threaten the SDGs?
The Lancet Public Health

Lancet Public Health
Sep 2020 Volume 5 Number 9 e460-e511
https://www.thelancet.com/journals/lanpub/issue/current

Comment
Communications to improve intention to receive HPV vaccine
Robert A Bednarczyk

Lancet Public Health
Sep 2020 Volume 5 Number 9 e460-e511
https://www.thelancet.com/journals/lanpub/issue/current

Articles
Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey
Kalyani Sonawane, Yenan Zhu, Jane R Montealegre, David R Lairson, Cici Bauer, Lindy U McGee, Anna R Giuliano, Ashish A Deshmukh

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy

Volume 98, Issue 3 Pages: 619-1020 September 2020
https://onlinelibrary.wiley.com/toc/14680009/current
Perspectives Free Access
Population Health in the Time of COVID‐19: Confirmations and Revelations
ANA V. DIEZ ROUX
Pages: 629-640
First Published: 18 August 2020
Milbank Quarterly Classics

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy

Revisiting Compression of Morbidity and Health Disparities in the 21st Century
PAULA M. LANTZ

Pages: 664-667
First Published: 18 August 2020

Nature
Volume 585 Issue 7824, 10 September 2020
http://www.nature.com/nature/current_issue.html

Comment | 08 September 2020
Don’t ignore genetic data from minority populations
Efforts to build representative studies are defeated when scientists discard data from certain groups. Instead, researchers should work to balance statistical needs with fairness.
Chief Ben-Eghan, Rosie Sun[…] & Simon Gravel

Nature
Volume 585 Issue 7824, 10 September 2020
http://www.nature.com/nature/current_issue.html

Review Article | 09 September 2020
Illuminating the dark spaces of healthcare with ambient intelligence
Albert Haque, Arnold Milstein & Li Fei-Fei
Abstract
Advances in machine learning and contactless sensors have given rise to ambient intelligence—physical spaces that are sensitive and responsive to the presence of humans. Here we review how this technology could improve our understanding of the metaphorically dark, unobserved spaces of healthcare. In hospital spaces, early applications could soon enable more efficient clinical workflows and improved patient safety in intensive care units and operating rooms. In daily living spaces, ambient intelligence could prolong the independence of older individuals and improve the management of individuals with a chronic disease by understanding everyday behaviour. Similar to other technologies, transformation into clinical applications at scale must overcome challenges such as rigorous clinical validation, appropriate data privacy and model transparency. Thoughtful use of this technology would enable us to understand the complex interplay between the physical environment and health-critical human behaviours.

Nature Biotechnology
Volume 38 Issue 9, 1 September 2020
https://www.nature.com/nbt/volumes/38/issues/9

Editorial | 28 August 2020
Thank you for sharing
The pandemic has highlighted long-standing, deep-rooted challenges to the sharing of biological samples. Greater attention is needed to mechanisms for incentivizing materials transfer.

Nature Biotechnology
Volume 38 Issue 9, 1 September 2020
https://www.nature.com/nbt/volumes/38/issues/9

News | 04 September 2020
Massive data initiatives and AI provide testbed for pandemic forecasting
Initiatives to gather massive epidemiological datasets aim to cut through national COVID-19 stats in a bid to understand the new coronavirus and aid public health policymakers.
Cormac Sheridan

Nature Medicine
Volume 26 Issue 9, 1 September 2020
https://www.nature.com/nm/volumes/26/issues/9

Guidelines for AI in clinical trials
The image on the cover illustrates the potential of artificial intelligence (AI) to enhance healthcare delivery. In this issue, new extensions of SPIRIT and CONSORT guidelines dedicated to randomized clinical trials involving AI delineate the reporting standards for these interventions, and Nimri and colleagues report the results of a randomized clinical trial evaluating the performance of an AI for optimizing insulin dosing in patients with type 1 diabetes.